1. Introduction {#s0005}
===============

The American Cancer Society estimates 63,230 new cases of uterine cancer and 11,350 uterine cancer-related deaths in 2018 ([@bb0055]). The World Health Organization defines undifferentiated endometrial carcinoma as "those lacking any evidence of differentiation" ([@bb0070]). A historically underrecognized and underreported subtype, undifferentiated carcinoma is present in approximately 9% of endometrial carcinomas, with only 29% purely undifferentiated endometrial carcinoma and the remaining 71% admixed with differentiated carcinoma ([@bb0010]; [@bb0065]). Undifferentiated endometrial cancers have been gaining attention in the pathology literature, with reports of hypermutated (mismatch repair deficiency), ultramutated (*POLE* mutated), copy number low (*PTEN* mutated) or copy number high (*TP53* mutated) molecular pathways ([@bb0050]), but literature regarding early clinical management is limited.

Undifferentiated histology has not been observed in hereditary nonpolyposis colorectal cancer (HNPCC) patients, but a subset of sporadic, *MLH1*-methylated tumors demonstrate undifferentiated histology ([@bb0015]; [@bb0025]). The undifferentiated tumors were weakly/patchy positive for pancytokeratin but negative for estrogen and progesterone receptor ([@bb0015]). In comparison to high grade endometrioid endometrial adenocarcinoma, which has 1--49% of glandular differentiation, patients with undifferentiated endometrial carcinoma also present with vaginal bleeding and/or pelvic pain but more often (54%--58%) present with advanced stage disease and more frequently (75%) die within 5 years of diagnosis ([@bb0010]; [@bb0075]). Pelvic and paraaortic lymph nodes are the common sites of metastasis ([@bb0075]; [@bb0005]), and advanced stage disease cases do not generally respond to conventional chemotherapy for endometrial adenocarcinoma.

2. Case reports ([Table 1](#t0005){ref-type="table"}) {#s0010}
=====================================================

2.1. Case 1 {#s0015}
-----------

A 69-year-old female (BMI 22.9 kg/m^2^) with postmenopausal bleeding was referred for undifferentiated endometrial carcinoma diagnosed on endometrial biopsy. She underwent an uncomplicated robotic assisted total laparoscopic hysterectomy with bilateral pelvic and para-aortic lymphadenectomy. Her pathology demonstrated International Federation of Gynecology and Obstetrics (FIGO) stage IA undifferentiated endometrial adenocarcinoma with intact expression of mismatch repair proteins. She completed 6 cycles of adjuvant carboplatin and paclitaxel. One month after completion of adjuvant chemotherapy, she reported clear fluid per vagina but had a normal pelvic examination. Computed tomography (CT) urogram showed no evidence of urinary tract fistula but demonstrated a soft tissue density above the vagina that was concerning for recurrent disease. A positron emission tomography (PET) demonstrated 3 distinct masses in the pelvis, ranging from 3.7--5.1 cm in single longest diameter and from 20.5 to 39.4 in SUV. Since her initial tumor was microsatellite stable, she was not a candidate for off-protocol pembrolizumab. A new biopsy was sent for molecular testing and estrogen and progesterone receptor status. The estrogen and progesterone receptors were not expressed. While awaiting those results, she elected to start cytotoxic chemotherapy. Several weeks after receiving her first cycle of single agent pegylated liposomal doxorubicin, she experienced rapid peritoneal disease progression, cachexia, and functional status decline. She transitioned to inpatient hospice and died within 3 weeks of initiating chemotherapy and \<6 weeks from the time her recurrence was diagnosed.Table 1Clinical and pathologic features of 2 patients with undifferentiated endometrial carcinoma.Table 1Case 1Case 2Clinical featuresAge at diagnosis, years6943Age at menopause, years52 (surgical, BSO)Not applicableBody mass index (kg/m^2^)22.923.2PresentationPostmenopausal bleedingAbnormal uterine bleedingInitial diagnosisHigh grade carcinoma, favor undifferentiated carcinomaPoorly differentiated carcinoma, unclear breast versus uterine originImaging findingsTVUS: Uterus normal size and shape, anteverted. Endometrium 0.8 mm anteriorly, 0.9 mm posteriorly with fluid in cavity. Total endometrial thickness 17 mm. Polyp on stalk with proximal attachment versus intracavitary fibroid measuring 2.3 × 1.6 × 2.0 cm. Ovaries not visualized. No free fluid.TVUS: 5.9 cm intrauterine mass, 3.3 cm complex right ovarian mass, no free fluid. CT CAP: Uterus markedly enlarged with suggestion of multiple fibroids. Uterine cavity filled with fluid. No lymphadenopathy. Small 2 mm focus of pleural thickening in left chest.Surgical managementRATLH BPPALNDRAH BSO BPPALND omental biopsiesOperative findingsSuperficial myometrial invasion. Large amount of necrotic tumor in lower uterine segment.Uterus bulbous and irregular with distended lower uterine segment. Parametria free. 200 mL bloody ascites upon abdominal entry. Enlarged, firm bilateral pelvic and right para-aortic lymph nodes.FIGO surgical stageIAIIIBPostoperative managementChemotherapy (6 cycles carboplatin + paclitaxel)Chemotherapy (3 cycles of carboplatin + paclitaxel)First postoperative recurrence or progression6 months4 monthsImaging findings at recurrencePET: 5.1 × 3.5 cm midline pelvic mass with SUV 39.4, 3.7 × 3.0 cm left pelvic mass with SUV 33.8, ill-defined hypermetabolic soft tissue along right pelvic sidewall with SUV 20.5CT CAP: 13 × 15 × 9 cm pelvic mass occupying the pelvis, displacing the urinary bladder and encasing vasculature including the iliac vesselsRecurrence or progression managementChemotherapy (1 cycle pegylated liposomal doxorubicin) followed by inpatient hospiceLeft percutaneous nephrostomy tube placement, Immunotherapy (1 cycle of pembrolizumab), followed by transfer to other care providerClinical historyGERDBreast cancer at age 30Family historyBreast cancer (sister at 47, mother at 42), Appendiceal cancer (mother at 78), Ovarian cancer (maternal aunt at 54), Colon cancer (paternal grandfather at 80)No family history of cancerGenetic testingBRCA 1/2 wildtypeATM VUS c.22117C \> T, BRIP1 VUS c.1442G \> A, CHEK2 VUS c.1111C \> TStatus at last follow-upDeceased (7 months after initial diagnosis)Unknown (moved out of country)  Pathologic featuresTumor locationRight uterine cornuEndometrial cavityTumor size1.7 × 1.5 × 1.0 cm6.7 × 3.5 × 3.0 cmMyometrial invasion20% of myometrium (2/10 mm)50% myometrium (8/16 mm)Lymphovascular space invasionAbsentPresent in parametriumCervical stromal invasionAbsentAbsentOvaries and fallopian tubesAbsentPresent in ligamentous soft tissues adjacent to left ovaryPelvic lymph nodesAbsentAbsentPara-aortic lymph nodesAbsentAbsentMismatch repair protein expressionPresentMLH-1, PMS-2 absent; MLH1 promoter methylation detectedEstrogen and progesterone receptor expressionAbsentNot done[^2]

2.2. Case 2 {#s0020}
-----------

A 43-year-old female (BMI 23.2 kg/m^2^) with a personal history of breast cancer 12 years prior presented with several weeks of abnormal uterine bleeding. Endometrial biopsy demonstrated a poorly differentiated carcinoma of breast versus endometrial origin. She underwent radical abdominal hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic lymphadenectomy, right para-aortic lymphadenectomy and omental biopsies. Her surgical pathology was initially reported as FIGO stage IB poorly differentiated endometrial adenocarcinoma. Outside pathology review reported a FIGO stage IIIB dedifferentiated carcinoma (predominantly undifferentiated with focal adenocarcinoma with mixed endometrioid and mucinous features), with lymphovascular invasion present in the parametrium and metastatic adenocarcinoma involving the ligamentous soft tissues adjacent to the left ovary, though there was no metastatic carcinoma involving the ovaries proper or fallopian tubes. She started adjuvant carboplatin and paclitaxel six weeks after surgery. During her office follow up after her third cycle of chemotherapy, she complained of sciatic nerve pain that had been worsening over several weeks. A CT was ordered for further evaluation and demonstrated a 13 × 15 × 9 cm pelvic mass displacing the urinary bladder, encasing vasculature (including iliac vessels), tracking beneath the psoas muscle and causing moderate left hydronephrosis. Given progression of disease while on active treatment, her fourth cycle of carboplatin and paclitaxel was held. A left percutaneous nephrostomy tube was placed for management of her hydronephrosis. Her immunohistochemistry demonstrated loss of expression of MLH1 and PMS2, so she was started on pembrolizumab. Shortly after her first treatment, she and her family felt that continued declined was inevitable and elected to return to her country of origin to seek medical care with more family and social support.

3. Discussion {#s0025}
=============

Although the pathology literature addressing undifferentiated and dedifferentiated endometrial carcinoma has increased over the past few years, PubMed search results using terms undifferentiated endometrial carcinoma and dedifferentiated endometrial carcinoma demonstrate scant medical or surgical oncology literature regarding management of these patients. Undifferentiated carcinomas represent a rare but extraordinarily aggressive subset of endometrial cancers. Multiple reports characterize the immunohistochemical profile and molecular pathways ([@bb0050]; [@bb0015]; [@bb0025]; [@bb0075]; [@bb0005]; [@bb0020]; [@bb0035]; [@bb0040]; [@bb0045]; [@bb0080]; [@bb0090]), including rates of loss of expression of mismatch repair proteins as high as 58% (n = 7) in undifferentiated endometrial carcinoma ([@bb0075]). Also referenced as "grade 4" tumors, undifferentiated carcinomas have higher likelihood of advanced stage at diagnosis and higher 5-year mortality as compared to high grade endometrioid endometrial adenocarcinomas ([@bb0010]; [@bb0075]). Undifferentiated carcinomas of the endometrium can be associated with a differentiated component, most often FIGO grade 1--2 endometrioid adenocarcinoma ([@bb0060]). The University of Texas MD Anderson Cancer Center describes these as "dedifferentiated" ([@bb0010]; [@bb0065]; [@bb0060]) while the Memorial Sloan Kettering Cancer Center describes them as "combined undifferentiated and differentiated carcinomas" ([@bb0075]). The Department of Pathology at the MD Anderson Cancer Center put forth a refined definition of undifferentiated carcinoma as being characterized by proliferation of medium- or large-sized, monotonous epithelial cells growing in solid sheets without a pattern, with a complete absence of glandular differentiation and with absent or minimal (\<10%) neuroendocrine differentiation ([@bb0010]; [@bb0065]). Some of the earlier literature on undifferentiated carcinoma of the endometrium included cases of large and small cell carcinomas with neuroendocrine differentiation; however, more recently these have been classified as neuroendocrine carcinomas rather than included among undifferentiated carcinomas since they do display a form of differentiation ([@bb0005]). Undifferentiated carcinomas of the endometrium demonstrate heterogeneous expression of epithelial markers, with only 5--10% of cells positive for keratin in approximately 80--90% of cases ([@bb0065]). Regardless of the nomenclature, anywhere from 37 to 87% of undifferentiated carcinomas have been reported to be admixed with endometrioid adenocarcinoma ([@bb0010]; [@bb0075]; [@bb0060]) and carcinomas with an undifferentiated component are consistently reported to be more aggressive than high grade endometrioid adenocarcinomas ([@bb0090]; [@bb0030]). Perinuclear staining of cytokeratin and EMA, loss of expression of PAX-8, ER, PR and E-cadherin have been shown to be helpful in distinguishing undifferentiated carcinoma from endometrioid adenocarcinoma ([@bb0030]).

Undifferentiated carcinoma may develop from any of the four molecular pathways described by The Cancer Genome Atlas for endometrial carcinoma: hypermutated (mismatch repair deficiency), ultramutated (*POLE* mutated), copy number low (*PTEN* mutated) or copy number high (*TP53* mutated) ([@bb0050]). Among undifferentiated carcinomas, *POLE*-mutated tumors have been shown to have favorable prognosis, with diagnosis at earlier stages (8 of 9 patients stage I or II) and no deaths from disease after 4 years in one retrospective study of 21 patients ([@bb0020]).

The only case series identified in Obstetrics and Gynecology literature is a 20-year retrospective cohort in Turkey with 1690 cases of endometrial cancer identified, 18 (1.1%) of which were reported to be undifferentiated carcinomas ([@bb0085]). Four (22.2%) of those patients had early (stage I or II) disease, while fourteen (77.8%) had advanced (stage III or IV) disease. Six (33.3%) of the eighteen patients were lost to follow up after surgery. Among the remaining twelve patients, two (16.6%) experienced disease progression while on active treatment and died of the disease 6--7 months after initial surgery. Another two (16.6%) experienced disease recurrence 12 and 14 months after initial surgery: one had a distal vaginal recurrence treated with surgery and chemotherapy and had no evidence of disease six years later and one had a vaginal cuff and lung recurrence and was subsequently lost to follow up. While this study is one of the larger case reports available and the only one with a clinical rather than pathologic focus, it is limited by the large number of patients lost to follow up, lack of rigorous pathologic review and immunohistochemistry and diversity of adjuvant treatment.

In conclusion, reliable classification of undifferentiated carcinoma represents the first step in learning more about this clinical entity and which subset of patients may have a more favorable course; however, data remain scarce regarding approach to adjuvant treatment in this population. We have reported two patients who failed to achieve disease control after surgery with no evidence of residual disease followed by adjuvant carboplatin and paclitaxel; both rapidly declined in functional status shortly after institution of second line therapy. Given the poor response to standard therapy and the high portion of undifferentiated carcinomas of the endometrium with mismatch repair deficiency, it raises the question of whether early molecular testing and non-standard chemotherapy including immunotherapy should be considered as frontline therapy for this subset of patients.
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[^2]: *BSO* bilateral salpingo-oophorectomy, *TVUS* transvaginal ultrasound, *CT CAP* computed tomography of the chest, abdomen and pelvis, *RATLH* robotic assisted total laparoscopic hysterectomy, *BPPALND* bilateral pelvic and para-aortic lymph node dissection, *RAH* radical abdominal hysterectomy, *PET* positron emission tomography, *GERD* gastroesophageal reflux disease, *BRCA 1/2* breast cancer genes 1 and 2, *ATM* ataxia telangectasia mutated, *VUS* variant of unknown significance, *BRIP1* BRCA1 interacting protein C-terminal helicase 1, *CHEK2* checkpoint kinase 2.
